RxDoctor Payments DataLook up a doctor →

Apurva Modi, MD

Gastroenterology · Rockville, MDNPI 1558300137

Payments from drug & device makers

$3,256,872in general payments, 2019–2025

Across 2,031 payments — averaging $1603.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$1.1M
  • AbbVie$553K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$335K
  • Gilead$306K
  • Madrigal Pharmaceuticals$292K
  • Genentech, Inc.$165K
  • plus $518K from 22 others

What the payments were for

  • Consulting fees$17,0691%
  • Speaking & faculty fees$971,28285%
  • Travel & lodging$130,78511%
  • Food & beverage$20,3142%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,256,872 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.

See all gastroenterology providers in Maryland

Medicare billing

Part B allowed, 2024
$86,755
Medicare patients
289
Services billed
866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin154$481,961
EpclusaSofosbuvir/Velpatasvir17$401,160
RezdiffraResmetirom20$82,516
VemlidyTenofovir Alafenamide22$33,408
Ursodiol161$25,954
Everolimus16$24,789
Tacrolimus164$11,519
Mycophenolic AcidMycophenolate Sodium78$9,156
Mycophenolate Mofetil116$6,891
Sirolimus16$5,962
Azathioprine80$3,380
Entecavir48$3,237
Cyclosporine ModifiedCyclosporine, Modified13$3,227
Lactulose53$2,990
Spironolactone130$1,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$334,964$481,961154 claims
GileadEpclusa, Vemlidy$306,362$434,56839 claims
Madrigal PharmaceuticalsRezdiffra$292,153$82,51620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 gastroenterology providers in Maryland.

Other gastroenterology in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →